超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

德國Micromet?
Micromet創建于德國，總部現設在馬里蘭州的Rockville，該公司正在開發一款試驗性血癌治療藥物，目前處在中期試驗階段。

Micromet was founded in 1993 by a small team of entrepreneurial scientists from the University of Munich with a firm belief in the potential of T cell based therapies to treat cancer. Their vision was to develop a new class of drugs that mobilize T cells, the body's most potent killer cells, enabling them to detect and destroy normally unrecognizable cancer cells. Within a few short years, the Company demonstrated the clinical potential of its technology, referred to as BiTE? (Bi-specific T cell engager), with the publication of compelling results from a Phase 1 trial of its BiTE antibody Blinatumomab (MT103) in patients with non-Hodgkin's lymphoma. Micromet began trading on the Nasdaq Global Market under the symbol MITI following a May 2006 reverse merger with California-based CancerVax.

Today Micromet is an integrated biopharmaceutical company with a pipeline of promising drug candidates, a clinically validated technology platform and strong BiTE antibody partnerships with industry leaders.

Micromet Today
Our goal is to discover, develop and commercialize breakthrough therapies with the potential to deliver meaningful clinical benefit to oncology patients. Our lead product candidate blinatumomab (MT103) has demonstrated single-agent activity in both adult and pediatric patients with acute lymphoblastic leukemia and is now the subject of a broad based development program in this disease setting. MT110, our second BiTE antibody, is currently in development in patients with advanced solid tumors. We are also advancing a pipeline of promising preclinical candidates and have robust research capabilities fuelling our long-term growth.

Micromet is headquartered in Rockville, Maryland with a research facility in Munich, Germany.
?